Invex Therapeutics Ltd

Short Term Long Term Short Term Comparison Long Term Comparison
  • IXC
  • 1d-5.56%
  • 1w0.00%
  • 1m-4.49%
  • 1y-80.90%
ATH
  • ATH Price$1.67
  • ATH Date2020-05-22
  • % since ATH-94.89%
  • % to ATH1,858.82%
ATL
  • ATL Price$0.07
  • ATL Date2024-01-08
  • % from ATL19.72%
  • Last Low Price$0.071
  • Last Low Date2024-01-08
  • % From Last Low19.72%
IPO
  • IPO Price$0.60
  • % Current ROI USD-85.83%
  • ATH Price$1.67
  • % ROI ATH 234,507.04%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="IXC"]

Key Data [addtoany]

Current price $0.085
Sector Healthcare
Industry Biotechnology
Today's High/Low $0.085/$0.084
Volume 5,618.00
Previous Close $0.09
52 Week High/Low $0.63/$0.06
Market Cap 6,763,842.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0
Annualized Dividend $2.07
$0.085
[addtoany]

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial.
The company was incorporated in 2019 and is based in Subiaco, Australia.

Annual Data | Millions of US $ except per share data 2019-06-30
Cash on hand -
Receivables $0.09
Inventory -
Pre-Paid Expenses -
Other Current Assets -
Total Current Assets $12.26
Property, Plant, And Equipment -
Long-Term Investments -
Goodwill And Intangible Assets -
Other Long-Term Assets -
Total Long-Term Assets -
Total Assets $12.37
Total Current Liabilities $0.94
Long Term Debt -
Other Non-Current Liabilities -
Total Long Term Liabilities -
Total Liabilities $0.94
Common Stock Net $12.61
Retained Earnings (Accumulated Deficit) $-0.23
Comprehensive Income -
Other Share Holders Equity $-0.94
Share Holder Equity $11.44
Total Liabilities And Share Holders Equity -